首次FIT阴性或低风险腺瘤患者的第二次FIT筛查结果:来自全国FIT筛查项目的结果

IF 4.7 2区 医学 Q1 ONCOLOGY
Pernille Thordal Larsen, Susanne Fogh Jørgensen, Morten Rasmussen, Berit Andersen, Sisse Helle Njor
{"title":"首次FIT阴性或低风险腺瘤患者的第二次FIT筛查结果:来自全国FIT筛查项目的结果","authors":"Pernille Thordal Larsen,&nbsp;Susanne Fogh Jørgensen,&nbsp;Morten Rasmussen,&nbsp;Berit Andersen,&nbsp;Sisse Helle Njor","doi":"10.1002/ijc.35419","DOIUrl":null,"url":null,"abstract":"<p>In Denmark, participants in faecal immunochemical test (FIT) screening with low-risk adenomas are recommended a return to biennial FIT-screening. However, they participate less than the FIT-negative group (FIT<sub>1</sub>-negative) at subsequent screening. Further, it is not clear how much this group benefits from the subsequent screening. We aimed at comparing the CRC incidence before and at the next screening (FIT<sub>2</sub>) in the low-risk group to that of those having a FIT-negative result at first time FIT-screening. In this register-based cohort study, we estimated the incidence of interval CRC (ICRC) and results of FIT<sub>2</sub>, including the FIT<sub>2</sub>-positivity rate and rate of screen detected CRC (SDCRC). Relative risk (RR) comparing the low-risk group to FIT<sub>1</sub>-negatives was estimated. Adjustment for age and sex was performed with binary regression and presented with a 95% confidence interval (CI). Incidence of ICRC was 0.17% and 0.08% in the Low-risk group and FIT<sub>1</sub>-negative group, respectively, RR 2.18 (95%CI 1.51; 3.16). After adjustment, RR was 1.76 (95%CI: 1.22; 2.55). The FIT<sub>2</sub>-positivity rate was 14.4% and 4.4% for the Low-risk group and FIT<sub>1</sub>-negative group, respectively. At FIT<sub>2</sub>-screening, the detection of SDCRC was 0.36% and 0.16% in the low-risk and FIT<sub>1</sub>-negative group, respectively, RR 2.27 (95%CI: 1.46; 3.54), adjusted 1.83 (95% CI: 1.17; 2.85). Despite a recent colonoscopy, participants having low-risk adenomas detected at first colonoscopy in FIT-screening remain at a higher short-term risk of ICRC and SDCRC compared to the FIT<sub>1</sub>-negatives. Continuous participation in FIT-screening is important for the Low-risk group.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"157 4","pages":"698-708"},"PeriodicalIF":4.7000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ijc.35419","citationCount":"0","resultStr":"{\"title\":\"Screening outcomes at second FIT screening in individuals with a first time negative FIT-result or low-risk adenomas: Results from a nationwide FIT screening program\",\"authors\":\"Pernille Thordal Larsen,&nbsp;Susanne Fogh Jørgensen,&nbsp;Morten Rasmussen,&nbsp;Berit Andersen,&nbsp;Sisse Helle Njor\",\"doi\":\"10.1002/ijc.35419\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>In Denmark, participants in faecal immunochemical test (FIT) screening with low-risk adenomas are recommended a return to biennial FIT-screening. However, they participate less than the FIT-negative group (FIT<sub>1</sub>-negative) at subsequent screening. Further, it is not clear how much this group benefits from the subsequent screening. We aimed at comparing the CRC incidence before and at the next screening (FIT<sub>2</sub>) in the low-risk group to that of those having a FIT-negative result at first time FIT-screening. In this register-based cohort study, we estimated the incidence of interval CRC (ICRC) and results of FIT<sub>2</sub>, including the FIT<sub>2</sub>-positivity rate and rate of screen detected CRC (SDCRC). Relative risk (RR) comparing the low-risk group to FIT<sub>1</sub>-negatives was estimated. Adjustment for age and sex was performed with binary regression and presented with a 95% confidence interval (CI). Incidence of ICRC was 0.17% and 0.08% in the Low-risk group and FIT<sub>1</sub>-negative group, respectively, RR 2.18 (95%CI 1.51; 3.16). After adjustment, RR was 1.76 (95%CI: 1.22; 2.55). The FIT<sub>2</sub>-positivity rate was 14.4% and 4.4% for the Low-risk group and FIT<sub>1</sub>-negative group, respectively. At FIT<sub>2</sub>-screening, the detection of SDCRC was 0.36% and 0.16% in the low-risk and FIT<sub>1</sub>-negative group, respectively, RR 2.27 (95%CI: 1.46; 3.54), adjusted 1.83 (95% CI: 1.17; 2.85). Despite a recent colonoscopy, participants having low-risk adenomas detected at first colonoscopy in FIT-screening remain at a higher short-term risk of ICRC and SDCRC compared to the FIT<sub>1</sub>-negatives. Continuous participation in FIT-screening is important for the Low-risk group.</p>\",\"PeriodicalId\":180,\"journal\":{\"name\":\"International Journal of Cancer\",\"volume\":\"157 4\",\"pages\":\"698-708\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ijc.35419\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ijc.35419\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.35419","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

在丹麦,建议接受低风险腺瘤的粪便免疫化学试验(FIT)筛查的参与者再次进行两年一次的FIT筛查。然而,在随后的筛查中,他们的参与少于fit1阴性组(fit1阴性)。此外,尚不清楚这一群体从随后的筛查中获益多少。我们的目的是比较低风险组与首次FIT2筛查结果为阴性的人群在筛查前和下次筛查时的CRC发病率(FIT2)。在这项基于登记的队列研究中,我们估计了间隔期CRC (ICRC)的发病率和FIT2的结果,包括FIT2阳性率和筛查检测CRC (SDCRC)的率。估计低危组与fit1阴性组的相对危险度(RR)。对年龄和性别进行二元回归校正,并给出95%可信区间(CI)。低危组和fit1阴性组的ICRC发生率分别为0.17%和0.08%,RR为2.18 (95%CI 1.51;3.16)。校正后,RR为1.76 (95%CI: 1.22;2.55)。低危组和fit1阴性组的fit2阳性率分别为14.4%和4.4%。fit2筛查时,低危组和fit1阴性组的SDCRC检出率分别为0.36%和0.16%,RR为2.27 (95%CI: 1.46;3.54),调整后1.83 (95% CI: 1.17;2.85)。尽管最近进行了一次结肠镜检查,但与fit1阴性患者相比,在首次结肠镜检查中检测到低风险腺瘤的参与者仍然具有较高的ICRC和SDCRC短期风险。持续参与fit筛查对低风险人群很重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Screening outcomes at second FIT screening in individuals with a first time negative FIT-result or low-risk adenomas: Results from a nationwide FIT screening program

Screening outcomes at second FIT screening in individuals with a first time negative FIT-result or low-risk adenomas: Results from a nationwide FIT screening program

In Denmark, participants in faecal immunochemical test (FIT) screening with low-risk adenomas are recommended a return to biennial FIT-screening. However, they participate less than the FIT-negative group (FIT1-negative) at subsequent screening. Further, it is not clear how much this group benefits from the subsequent screening. We aimed at comparing the CRC incidence before and at the next screening (FIT2) in the low-risk group to that of those having a FIT-negative result at first time FIT-screening. In this register-based cohort study, we estimated the incidence of interval CRC (ICRC) and results of FIT2, including the FIT2-positivity rate and rate of screen detected CRC (SDCRC). Relative risk (RR) comparing the low-risk group to FIT1-negatives was estimated. Adjustment for age and sex was performed with binary regression and presented with a 95% confidence interval (CI). Incidence of ICRC was 0.17% and 0.08% in the Low-risk group and FIT1-negative group, respectively, RR 2.18 (95%CI 1.51; 3.16). After adjustment, RR was 1.76 (95%CI: 1.22; 2.55). The FIT2-positivity rate was 14.4% and 4.4% for the Low-risk group and FIT1-negative group, respectively. At FIT2-screening, the detection of SDCRC was 0.36% and 0.16% in the low-risk and FIT1-negative group, respectively, RR 2.27 (95%CI: 1.46; 3.54), adjusted 1.83 (95% CI: 1.17; 2.85). Despite a recent colonoscopy, participants having low-risk adenomas detected at first colonoscopy in FIT-screening remain at a higher short-term risk of ICRC and SDCRC compared to the FIT1-negatives. Continuous participation in FIT-screening is important for the Low-risk group.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
13.40
自引率
3.10%
发文量
460
审稿时长
2 months
期刊介绍: The International Journal of Cancer (IJC) is the official journal of the Union for International Cancer Control—UICC; it appears twice a month. IJC invites submission of manuscripts under a broad scope of topics relevant to experimental and clinical cancer research and publishes original Research Articles and Short Reports under the following categories: -Cancer Epidemiology- Cancer Genetics and Epigenetics- Infectious Causes of Cancer- Innovative Tools and Methods- Molecular Cancer Biology- Tumor Immunology and Microenvironment- Tumor Markers and Signatures- Cancer Therapy and Prevention
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信